Business
WILLOW BIOSCIENCES REPORTS FOURTH QUARTER AND FISCAL YEAR 2022 FINANCIALS AND OPERATIONS AND FILING OF ITS 2022 AIF
WILLOW BIOSCIENCES REPORTS FOURTH QUARTER AND FISCAL YEAR 2022 FINANCIALS AND OPERATIONS AND FILI...
About this update from Atlas Energy Corp.
[{"type":"text","content":"\n \n \n \n WILLOW BIOSCIENCES REPORTS FOURTH QUARTER AND FISCAL YEAR 2022 FINANCIALS AND OPERATIONS AND FILING OF ITS 2022 AIF\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n \n Reports Highest Quarterly and Annual Revenue in Company History with Significant Year-Over-Year Growth Expected for 2023\n \n \n \n \n \n \n CALGARY, AB\n \n and\n \n MOUNTAIN VIEW, Calif.\n \n \n ,\n \n \n March 21, 2023\n \n \n /CNW/ - Willow Biosciences Inc. (\"\n \n Willow\n \n \") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients is pleased to announce its financial and operating results for the three months and year ended\n \n December 31, 2022\n \n , and filing of its Annual Information Form (\"AIF\"). Selected financial and operational information is outlined below and should be read with Willow's audited consolidated financial statements (the \"Financial Statements\") and management's discussion and analysis (the \"MD&A\") as of\n \n December 31, 2022\n \n , which are available on SEDAR at\n \n \n www.sedar.com\n \n \n .\n \n \n \n \n \n \n \n \n \n \"Fiscal 2022 was a transformative year for Willow as we took significant steps to position the company for nearer term revenue creation, and more rapid and diversified commercial growth, all with a reduced cash burn,\" said Dr. Peter Seufer-Wasserthal, Willow's President and CEO. \"The result of these activities was our ability to successfully deliver on certain key milestones while posting the highest quarterly and annual revenue in the Company's history. We are proud of Willow's R&D team's dedication and execution and excited to showcase our capabilities in 2023 while delivering what we believe will be significant revenue growth and overall improved financial results.\"\n \n \n \n Highlights for the Quarter\n \n \n \n \n Added a new functional ingredient, astaxanthin, to the Company's product portfolio.\n \n \n Signed a Maste...